MKI67 and breast cancer: The strengths of this study lie in the sample size of our study, its detailed focus, and the valuable data on the epidemiological aspects of breast cancer, combined with a thorough analysis of histological subtypes and immunophenotypic markers (ER, PR, HER2 and Ki-67).